StockNews.com began coverage on shares of NantHealth (NASDAQ:NH – Get Rating) in a report published on Wednesday morning. The brokerage issued a hold rating on the stock.
NantHealth Price Performance
NantHealth stock opened at $3.46 on Wednesday. NantHealth has a one year low of $1.57 and a one year high of $15.75. The stock's 50 day moving average is $2.59 and its 200 day moving average is $1.16. The firm has a market cap of $26.68 million, a P/E ratio of -0.45 and a beta of 1.88.
Get
NantHealth alerts:
NantHealth (NASDAQ:NH – Get Rating) last released its quarterly earnings data on Thursday, November 3rd. The company reported ($0.13) EPS for the quarter. The firm had revenue of $16.63 million during the quarter.
Institutional Investors Weigh In On NantHealth
Several institutional investors have recently bought and sold shares of the stock. Goldman Sachs Group Inc. bought a new position in NantHealth during the 2nd quarter worth approximately $36,000. Hartline Investment Corp purchased a new position in shares of NantHealth in the second quarter valued at about $65,000. Millennium Management LLC purchased a new position in shares of NantHealth in the second quarter valued at about $110,000. Finally, Atria Wealth Solutions Inc. purchased a new position in shares of NantHealth in the first quarter valued at about $170,000. Institutional investors own 4.50% of the company's stock.
NantHealth Company Profile
(Get Rating)
NantHealth, Inc is an evidence-based, personalized healthcare company, which engages in the provision of treatment for critical diseases such as cancer. The firm empowers treatment decisions, improves patient outcomes, validates treatment options, enables high-quality care, lowers costs, ensures appropriate reimbursement, and streamlines implementation and deployment.
Featured Articles
- Get a free copy of the StockNews.com research report on NantHealth (NH)
- Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
- Zimmer Biomet Beats on Earnings, Growth May be Priced In
- AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
- Ford Stock Going Forward After Big Earnings Flop
- Insiders And Institutions Buy Wolverine Worldwide
Receive News & Ratings for NantHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantHealth and related companies with MarketBeat.com's FREE daily email newsletter.
StockNews.com開始對股票進行報道NantHealth(納斯達克：NH-GET評級)在週三上午發佈的一份報告中。該券商對該股發佈了持有評級。
NantHealth價格表現
週三，NantHealth的股票開盤報3.46美元。NantHealth的一年低點為1.57美元，一年高位為15.75美元。該股的50日移動均線切入位在2.59美元，200日移動均線切入位在1.16美元。該公司的市值為2668萬美元，本益比為-0.45，貝塔係數為1.88。
到達
NantHealth警報：
NantHealth(納斯達克：NH-GET評級)最近一次發佈季度收益數據是在11月3日星期四。該公司公佈了該季度每股收益(0.13美元)。該公司本季度的收入為1663萬美元。
機構投資者看好NantHealth
幾家機構投資者最近買賣了該股的股票。高盛股份有限公司在第二季度購買了價值約36,000美元的南洋健康新頭寸。Hartline Investment Corp在第二季度購買了NantHealth的新頭寸，價值約65,000美元。Millennium Management LLC在第二季度購買了NantHealth的新頭寸，價值約11萬美元。最後，Atria Wealth Solutions Inc.在第一季度購買了NantHealth的新頭寸，價值約17萬美元。機構投資者持有該公司4.50%的股份。
NantHealth公司簡介
(獲取評級)
NantHealth，Inc.是一家以證據為基礎的個性化保健公司，致力於為癌症等危重疾病提供治療。該公司支持治療決策，改善患者結局，驗證治療選項，實現高質量護理，降低成本，確保適當的報銷，並簡化實施和部署。
專題文章
- 免費獲取StockNews.com關於NantHealth(NH)的研究報告
- 細價股值得嗎？你應該投資細價股嗎？
- Zimmer Biomet盈利節節攀升，增長可能被計入價格
- 人工智慧軟體製造商EPAM號稱科技板塊漲幅最大
- 福特股票在盈利大幅下滑後繼續前進
- 內部人士和機構收購金剛狼全球
接受《NantHealth Daily》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對NantHealth和相關公司的最新新聞和分析師評級的每日簡要摘要。
